Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Recruiting 4

Sponsor Class

OTHER 4

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Sarcoma 1Myeloid 1Lymphoid 1CNS 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Biphenotypic, Acute 1Glioma 1Burkitt Lymphoma 1

Interventions

Specimen Handling 439Magnetic Resonance Spectroscopy 341pembrolizumab 288Biopsy 241Carboplatin 230Cisplatin 193Cyclophosphamide 185Paclitaxel 164Nivolumab 153Gemcitabine 151Bevacizumab 121Radiotherapy 119Dexamethasone 113fludarabine 99Pemetrexed 99Fluorouracil 94durvalumab 90Doxorubicin 90venetoclax 89Docetaxel 89Radiation 88Oxaliplatin 88Rituximab 87atezolizumab 84Leucovorin 79Capecitabine 75Prednisone 74Lenalidomide 69Etoposide 69X-Rays 65

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Blood Component Removal × 30 days × Clear all
NCT05418088 2026-05-29

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Ohio State University Comprehensive Cancer Center

Phase 1 Recruiting
54 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Prolymphocytic, B-Cell

NCT07428993 2026-05-19

Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma

St. Jude Children's Research Hospital

Phase 2 Recruiting
41 enrolled
Sarcoma

Osteosarcoma

NCT06928662 2026-05-15

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
36 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06964737 2026-05-08

Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas

Ohio State University Comprehensive Cancer Center

Phase 1 Recruiting
30 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡